BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.39
−14.36%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.0%
- EBIT
- -5.3%
- EPS
- +97.0%
- Free cash flow
- +39.8%
- Operating cash flow
- +35.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +9.6%
- EBIT
- +10.1%
- Net income
- -9.0%
- EPS
- +89.2%
- Free cash flow
- +58.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026